Method and device for analyzing whether mutation is located in same gene haplotype
Through multi-allosite splitting, HGVS correction and automated audit, it is possible to accurately determine whether the mutation is located in the same genomic haplotype, solving the problems of cumbersome detection and high false positive rates in the existing technology, and improving the detection efficiency and accuracy. Provides better guidance for the treatment of tumor patients.
Patent Information
- Application Number
- CN202410959561.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-17
- Publication Date
- 2024-11-15
AI Technical Summary
In the prior art, when judging whether the mutation is in the same genotype, there are problems such as complicated detection, long time-consuming, high false positive rate and low manual review efficiency, which affects the determination of the treatment plan for tumor patients.
Through multi-allosite splitting, HGVS correction and site automation audit, the difference set and intersection of the supporting reads of mutation sites are determined to achieve an accurate determination of whether the mutation is located in the same genomic haplotype.
It improves the accuracy and efficiency of mutation detection, reduces false positives, provides fast and accurate judgment of mutation location, and provides guidance for accurate treatment of tumor patients.
Smart Images

Figure CN118969080A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biological information analysis, and in particular relates to a method and a device for analyzing whether mutations are located in the same gene haplotype. Background Art
[0002] The drugs currently used for first-line, second-line and adjuvant treatment of cancer patients can significantly improve the prognosis of cancer patients. Despite the significant efficacy, drug resistance inevitably occurs and leads to disease progression. For example, EGFR C797X is a common on-target resistance mutation in patients with non-small cell lung cancer (NSCLC) after treatment with osimertinib. Previous studies have shown that whether different mutations are located on the same allele directly affects the patient's treatment plan. For example, patients with EGFR C797S mutations and no EGFR T790M mutations are sensitive to first- and second-generation EGFR-TKIs, while patients with EGFR T790M and EGFR C797S mutations that are located on different haplotypes are treated with first- and third-generation EGFR-TKIs in combination. Patients with EGFR T790M and EGFR C797S mutations that are located on the same haplotype will be resistant to single-drug first-, second- and third-generation EGFR-TKIs and need to be treated with single-drug or drug combination regimens in new studies. Therefore, determining whether different mutations are located on the same gene haplotype is critical for determining the patient's treatment plan.
[0003] Direct detection based on Sanger sequencing technology is complicated, time-consuming, and requires a high mutation frequency. NGS-based methods can detect mutations quickly and accurately at the same time. However, in the NGS analysis of clinical samples, in order to avoid filtering out meaningful positive mutations, mutation detection software (such as freebayes, vardict, varscan, and mutect2) usually relaxes the detection threshold and expands the number of mutations detected. Relaxing the quality control threshold of mutation detection will introduce false positive mutations, so a large number of mutation sites need to be manually inspected. Manual review has many limitations, such as: (1) Different people review the same sample, which is prone to subjective misjudgment; (2) The training cost of reviewers is high, and there is a gap in the level of different reviewers; (3) The efficiency of manual review is low, especially when there are many expedited samples, the reviewer's workload is heavy.
[0004] Therefore, there is still a need for a method and device based on multi-gene testing that can accurately and quickly identify whether mutations are located in the same gene haplotype, so as to provide guidance for the precise treatment of cancer patients. Summary of the invention
[0005] In order to solve at least some of the technical problems in the above-mentioned prior art, the present invention provides a method and device for analyzing whether a mutation is located in the same gene haplotype. The method of the present invention obtains a set of supporting reads of each mutation site to be analyzed through multi-allelic site splitting, HGVS correction, and site automatic review, and further determines the difference and intersection of the set to accurately determine whether the mutation is located in the same gene haplotype. Specifically, the present invention includes the following contents.
[0006] In a first aspect of the present invention, a method for analyzing whether mutations are located in the same gene haplotype is provided, comprising the following steps:
[0007] (1) performing multi-allelic site splitting using the mutation result file, the sample comparison result file, the gene transcript file, and the mutation site information to be analyzed as input parameters to obtain the split mutation result file;
[0008] (2) performing HGVS correction on the split mutation result file to obtain corrected data;
[0009] (3) performing site-automatic review on the corrected data to obtain a set of supporting reads for each mutation site to be analyzed;
[0010] (4) Determine the difference and intersection of the sets. If the number of supporting reads in the intersection is greater than or equal to 3 and greater than or equal to the minimum number of supporting reads in all difference sets, then the mutation to be analyzed is determined to be located in the same gene haplotype; otherwise, it is determined that the mutation is not located in the same gene haplotype.
[0011] In the present invention, the mutation sites to be analyzed include at least two mutations whose distance between any mutation sites is less than the sequencing read length, and such mutations include point mutations, insertion mutations or deletion mutations. It is understood that the mutations can be mutations of more than 2 sites within the sequencing read length on the same gene, such as mutations of 3 or 4 sites. Taking EGFR as an example, two or more mutations such as T790M, L792H, G796R and C797S on the EGFR gene can be combined to determine whether they are located in the same gene haplotype.
[0012] In certain embodiments, according to the method described herein, the mutation comprises mutations at at least two sites, and the distance between the sites is less than 150 bp, preferably less than 145 bp, further preferably less than 140 bp, further preferably less than 135 bp, more preferably less than 130 bp, for example less than 130, 125, 120, 115, 110, 105, 100, 95, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20 bp.
[0013] In certain embodiments, according to the method described herein, the sample comprises a tumor tissue sample or a fluid sample, wherein the fluid sample includes but is not limited to blood, synovial fluid, cerebrospinal fluid, etc., and the above tissue or fluid samples containing ctDNA are preferred.
[0014] In certain embodiments, according to the method of the present invention, wherein the multi-allelic site splitting comprises:
[0015] (I) splitting the alleles of the test sample genome sequence separated by delimiters in the mutation result file into multiple lines;
[0016] (II) correcting the bases of the genome sequence of the test sample according to the differences between the bases of the genome sequence of the test sample after the splitting and the reference (REF) bases to obtain corrected base information;
[0017] (III) correcting the physical position of the mutation site according to the base information of the corrected test sample genome sequence and the reference base information;
[0018] Further includes (IV): annotation information of the split mutation.
[0019] In certain embodiments, according to the method described herein, the annotation information includes allele balance, allele balance probability, the total number of all mutant alleles, allele frequency, the number of reads supporting a specific mutant allele, the CIGAR value of a specific mutant allele, the depth ratio of a specific mutant allele, the probability of end positioning, the length of a specific mutant allele, the number of reads supporting the reverse chain of the mutant allele, the number of reads supporting the forward chain of the mutant allele, and the mutation type.
[0020] In certain embodiments, according to the method of the present invention, wherein the HGVS correction comprises:
[0021] (a) Input mutation detection results: the mutation detection results include the type, position and reference sequence of the mutation;
[0022] (b) mutation classification: classifying the mutation detection results to distinguish between c-point mutations and p-point mutations;
[0023] (c) Correction of point mutation c;
[0024] (d) Correction of p point mutation;
[0025] (e) Perform mutation annotation.
[0026] In certain embodiments, according to the method of the present invention, wherein the correction of the c point mutation comprises:
[0027] Identify cDNA sequences: Determine cDNA sequences based on reference genome and transcript information;
[0028] Mutation mapping: Mapping sequencing reads onto cDNA sequences to determine the exact location of the mutation;
[0029] Splice site analysis: Check whether the mutation is located at or near the splice site;
[0030] Coding region analysis: Determine if the mutation is located in the coding region and analyze its effect on the coding sequence.
[0031] In certain embodiments, according to the method of the present invention, wherein the p-point mutation correction comprises:
[0032] Protein sequence determination: translating the cDNA sequence into a protein sequence;
[0033] Prediction of mutation effects: Analyze the impact of mutations on protein sequences;
[0034] Functional domain analysis: determine whether the mutation occurs in the functional domain or structural domain of the protein;
[0035] Genetic codon table correction: Correction of mutation annotation errors.
[0036] In certain embodiments, according to the method of the present invention, the automated review comprises:
[0037] (1′) Determine that the read alignment quality of the supporting site is higher than 30;
[0038] (2') confirm that the quality of the mutated base is higher than 20;
[0039] (3′) confirm that the mutation position is not located at the end of the read segment;
[0040] (4′) determining that the edit distance tag of the read segment is less than 4;
[0041] (5') Confirm that there is no plus-minus strand preference and that the mutation site is not located in a genomic repetitive region.
[0042] In the present invention, if the sample is a tumor tissue, its sequencing depth is not less than 300X; if the sample is a blood sample, its sequencing depth is not less than 1500X. It can be understood that the judgment threshold can be selected according to the sample to be tested and the sequencing depth. For example, in a tissue sample, when the sequencing depth is 300X and the mutation abundance is above 1%, the number of supporting reads in the intersection is selected to be greater than or equal to 3. For blood samples and other samples to be tested, a suitable judgment threshold can be selected according to the mutation abundance, for example, when it is above 0.1% or 0.5%.
[0043] A second aspect of the present invention provides a device for analyzing whether mutations are located in the same gene haplotype, comprising:
[0044] A data acquisition unit, which is used to acquire sample sequencing reads from a sequencing device, and perform data analysis based on the sequencing reads to obtain data to be split including a mutation result file, a sample comparison result file, a gene transcript file, and information on mutation sites to be analyzed;
[0045] A data splitting unit, which is used to split the data to be split into multiple alleles to obtain a mutation result file after the splitting;
[0046] An HGVS correction unit, which is used to perform HGVS correction on the split mutation result file to obtain corrected data;
[0047] A site automated review unit, which is used to perform site automated review on the corrected data to obtain a set of supporting read segments for each mutation site to be analyzed;
[0048] A result determination unit is used to determine the difference and intersection of the sets, determine whether the mutations are located in the same gene haplotype, and if the number of supporting reads in the intersection is greater than or equal to 3 and greater than or equal to the minimum number of supporting reads in all differences, then the mutations to be analyzed are determined to be located in the same gene haplotype; otherwise, it is determined that the mutations to be analyzed are not located in the same gene haplotype.
[0049] According to a third aspect of the present invention, a computer-readable storage medium is provided, wherein the computer-readable storage medium stores a computer program, and when the computer program is executed by a processor, the steps of the method described in the present invention are implemented.
[0050] According to a fourth aspect of the present invention, an electronic device is provided, which includes a memory, a processor, and a computer program stored in the memory and executable on the processor, wherein the processor implements the steps of the method described in the present invention when executing the computer program.
[0051] The present invention does not require the design of amplification primers and probes for the sites of different mutations to be analyzed, and can perform different configuration mutation analysis while detecting other drug sites, and can detect multiple groups of mutation pairs at the same time. In addition, the present invention does not require re-alignment and mutation detection, and uses the BAM file produced in the NGS test to extract high-quality reads (e.g., high base quality, high alignment quality, and uniformly distributed reads) of different mutation sites to be detected, and uses the number of reads of the intersection of the two groups of reads to be greater than the number of reads that only support one mutation to determine whether the site to be tested is located in the same gene haplotype, while realizing different configuration interpretations. The automated review of false positives at the site is increased. Therefore, the present invention has the advantages of high detection efficiency, fast speed, and high sensitivity, and can provide guidance for subsequent treatment of tumor patients. BRIEF DESCRIPTION OF THE DRAWINGS
[0052] Figure 1 Schematic diagram of the logic of the method of the present invention.
[0053] Figure 2 Schematic diagram of different mutation configurations.
[0054] Figure 3 This is the detection result of EGFR T790M and C797S in the same gene haplotype in clinical samples.
[0055] Figure 4 These are the detection results of EGFR T790M and C797S located in different gene haplotypes in clinical samples.
[0056] Figure 5 It is the difference and intersection of the sets of supporting reads for each pair of sites with different mutation configurations to be detected. DETAILED DESCRIPTION
[0057] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0058] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that the upper and lower limits of the scope and each intermediate value therebetween are specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0059] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as commonly understood by those skilled in the art to which the invention belongs. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials related to the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0060] Example 1
[0061] The following is a method for analyzing whether mutations are located in the same gene haplotype based on NGS.
[0062] The input parameters include the mutation result file, the comparison result file of the sample, the common transcript file of the gene, and the cis-trans mutation pair to be detected. The output result is the integrated mutation result file (format VCF file). If the T790M and C797S mutations do not exist in the sample at the same time, the mutation result file will not be adjusted; if the sample has the information of the configuration of the cis-trans mutation pair to be detected in the file, taking EGFR T790M and C797S as an example, the p-point information of the newly added mutation result is 'p.T790M and p.C797S are different gene haplotypes' or 'p.T790M and p.C797S are the same gene haplotype', so that it can accurately match and output the corresponding drug application information when matching with the database.
[0063] The data analysis schematic diagram of the present invention is as follows Figure 1 As shown in the figure, first, the BAM and VCF files generated in the NGS test are used to split the multi-allelic sites in the VCF. Then, the mutations in the VCF are corrected by HGVS to avoid mismatching with sites of different mutation configurations to be detected due to uncorrected sites.
[0064] The corrected sites were reviewed using an automated review tool, with the conditions that the read alignment quality of the supporting sites was higher than 30, the quality of the mutant base was higher than 20, the mutation position was not located at the end of the read, the edit distance label of the read was less than 4, there was no positive or negative strand preference, and the mutation site was not in the genomic repetitive region.
[0065] Finally, the sites of different mutation configurations to be detected are used to determine the difference (unique1, unique2, unique3) and intersection (intersect) of the sets of their respective supporting reads. If intersect ≥ 3 and intersect ≥ min (unique1, unique2, unique3), it is judged to be a cis configuration, otherwise it is judged to be a trans configuration.
[0066] In the method of the present invention, the multi-allelic site splitting includes: the detected mutation will appear as a compound mutation in the VCF (Varinant Call Format) file, and multiple ALT alleles will be separated by a separator. In view of this situation, the present invention splits such mutations into multiple lines. In the process of splitting into multiple lines: (1) for the splitting of ALT, the ALT base is corrected according to the difference between the split ALT base and the REF base; (2) based on the corrected ALT base and REF base, the physical position of the mutation site is corrected to avoid the situation where the ALT base does not match the physical position when there is a multi-base mutation; (3) for the splitting of annotation information, in order to match the split mutation, the relevant information of the split mutation needs to be split. The relevant information that needs to be split includes: allele balance (AB), allele balance probability (ABP), the total number of all mutant alleles (AC), allele frequency (AF), specific mutant allele support read number (AO), specific mutant allele CIGAR value (CIGAR), specific mutant allele depth ratio (DPRA), end positioning probability (EPP), specific mutant allele length (LEN), mutant allele reverse chain support read number (SAR), mutant allele forward chain support read number (SAF), mutation type (TYPE).
[0067] In the present invention, HGVS correction includes: for different configuration mutation pairs to be detected, they are usually represented by c-point and p-point in the commonly used gene transcripts in the NCCN guidelines, CSCO guidelines or expert consensus. In order to correctly match the c-point and p-point in the commonly used transcripts, site correction is required, and the process of correcting the c-point and p-point mutations includes:
[0068] (1) Input data: Input mutation detection results, which include information such as mutation type, location, and reference sequence;
[0069] (2) Mutation classification: Classify the input mutation data into c-point mutations (such as SNPs, insertions, deletions, etc.) and p-point mutations (such as amino acid substitutions, insertions, deletions, etc.);
[0070] (3)c point mutation correction:
[0071] Identify cDNA sequences: Determine cDNA sequences based on reference genome and transcript information;
[0072] Mutation mapping: Mapping sequencing reads onto cDNA sequences to determine the exact location of the mutation;
[0073] Splice site analysis: Check whether the mutation is located at or near the splice site, as this may affect the splicing process;
[0074] Coding region analysis: Determine whether the mutation is located in the coding region and analyze its potential impact on the coding sequence;
[0075] (4) p point mutation correction:
[0076] Protein sequence determination: translation of cDNA sequence into protein sequence;
[0077] Prediction of mutation effects: Analyze the effects of mutations on protein sequences, such as missense mutations, nonsense mutations, protein truncation, etc.
[0078] Functional domain analysis: Determine whether the mutation occurs in the functional domain or structural domain of the protein, which may affect the function of the protein;
[0079] Genetic codon table correction: taking into account different genetic codon tables, correcting mutation annotation errors that may be caused by codon duplication;
[0080] (5) Mutation Annotation: Provide detailed annotations of mutations, including their possible effects on gene expression and protein function.
[0081] Verification Example
[0082] The following are the analysis results of known clinical samples using the method of the present invention. The analysis results of different mutation configurations show that the method of the present invention has extremely high accuracy and precision. As can be seen from Table 1, the accuracy and precision of the method of the present invention both reach 100%, and it can accurately determine whether the mutations in the clinical samples are located in the same gene haplotype. As can be seen from Table 2, the false detection rate of the method of the present invention is 0%, that is, it will not cause misjudgment of clinical samples with target mutations of different mutation configurations.
[0083] Table 1
[0084] Different mutation configurations exist There are no real different mutation configurations Tools detect the presence of different mutation configurations 8 0 The tool detects the absence of different mutation configurations 0 95
[0085] Table 2
[0086]
[0087]
[0088] Example 2
[0089] The following shows a device for analyzing whether mutations are located in the same gene haplotype, which includes:
[0090] A data acquisition unit, which is used to acquire sample sequencing reads from a sequencing device, and perform data analysis based on the sequencing reads to obtain data to be split including a mutation result file, a sample comparison result file, a gene transcript file, and information on mutation sites to be analyzed;
[0091] A data splitting unit, which is used to split the split data into multiple alleles to obtain a mutation result file after the split;
[0092] An HGVS correction unit, which is used to perform HGVS correction on the split mutation result file to obtain corrected data;
[0093] A site automated review unit, which is used to perform site automated review on the corrected data to obtain a set of supporting read segments for each mutation site to be analyzed;
[0094] A result determination unit is used to determine the difference and intersection of the sets, determine whether the mutations are located in the same gene haplotype, and if the number of supporting reads in the intersection is greater than or equal to 3 and greater than or equal to the minimum number of supporting reads in all differences, then the mutations to be analyzed are determined to be located in the same gene haplotype; otherwise, it is determined that the mutations to be analyzed are not located in the same gene haplotype.
[0095] In the device of the present invention, the mutation to be analyzed includes mutations at at least two sites, and the distance between the sites is less than 150 bp.
[0096] In the device of the present invention, the sample to be tested includes a tumor tissue sample or a fluid sample.
[0097] In the device of the present invention, the data splitting unit implements the steps of splitting the alleles of the test sample genome sequence separated by a separator in the mutation result file into multiple lines, wherein the bases of the test sample genome sequence are corrected according to the difference between the bases of the split test sample genome sequence and the reference bases to obtain the corrected base information, and the physical position of the mutation site is corrected according to the base information of the corrected test sample genome sequence and the reference base information;
[0098] The data splitting unit further implements the step of splitting the annotation information of the mutation;
[0099] The annotation information includes allele balance, allele balance probability, the total number of all mutant alleles, allele frequency, number of reads supporting a specific mutant allele, CIGAR value of a specific mutant allele, depth ratio of a specific mutant allele, end positioning probability, length of a specific mutant allele, number of reads supporting the reverse chain of the mutant allele, number of reads supporting the forward chain of the mutant allele, and mutation type.
[0100] In the device of the present invention, the HGVS correction unit is implemented including the following steps:
[0101] (a) Input mutation detection results: the mutation detection results include the type, position and reference sequence of the mutation;
[0102] (b) mutation classification: classifying the mutation detection results to obtain c-point mutations and p-point mutations;
[0103] (c) performing c point mutation correction and p point mutation correction respectively;
[0104] (d) Mutation annotation.
[0105] In the device of the present invention, the c point mutation correction of the HGVS correction unit includes:
[0106] Identify cDNA sequences: Determine cDNA sequences based on reference genome and transcript information;
[0107] Mutation mapping: Mapping sequencing reads onto cDNA sequences to determine the exact location of the mutation;
[0108] Splice site analysis: Check whether the mutation is located at or near the splice site;
[0109] Coding region analysis: Determine if the mutation is located in the coding region and analyze its effect on the coding sequence.
[0110] In the device of the present invention, the p-point mutation correction of the HGVS correction unit includes:
[0111] Protein sequence determination: translating the cDNA sequence into a protein sequence;
[0112] Prediction of mutation effects: Analyze the impact of mutations on protein sequences;
[0113] Functional domain analysis: determine whether the mutation occurs in the functional domain or structural domain of the protein;
[0114] Genetic codon table correction: Correction of mutation annotation errors.
[0115] In the device of the present invention, the automated audit unit implements the following steps:
[0116] (1′) Determine that the read alignment quality of the supporting site is higher than 30;
[0117] (2') confirm that the quality of the mutated base is higher than 20;
[0118] (3′) confirm that the mutation position is not located at the end of the read segment;
[0119] (4′) determining that the edit distance tag of the read segment is less than 4;
[0120] (5') Confirm that there is no plus-minus strand preference and that the mutation site is not located in a genomic repetitive region.
[0121] It should be understood that the division of the various units of the above device is only a division of logical functions. In actual implementation, they can be fully or partially integrated into one physical entity, or they can be physically separated. And these units can all be implemented in the form of software calling through processing elements; they can also be all implemented in the form of hardware; some units can also be implemented in the form of software calling through processing elements, and some units can be implemented in the form of hardware. For example, the data processing unit can be a separately established component, or it can be integrated in a chip of the above device. In addition, it can also be stored in the above device in the form of program code, and called and executed by a processing element of the above device. The implementation of other units is similar. In addition, these units can be fully or partially integrated together, or they can be implemented independently. The element described here can be an integrated circuit with signal processing capabilities. In the implementation process, the above units can be completed by hardware integrated logic circuits or software instructions.
[0122] For example, the above units may be one or more integrated circuits configured to implement the above methods, such as one or more application specific integrated circuits (ASICs), or one or more digital signal processors (DSPs), or one or more field programmable gate arrays (FPGAs). For another example, when a certain unit above is implemented in the form of a processing element scheduling program code, the processing element may be a general-purpose processor, such as a central processing unit (CPU) or other processors that can call program code. For another example, these units may be integrated together and implemented in the form of a system-on-a-chip (SOC).
[0123] Based on this, the present invention also provides a computer-readable storage medium, on which a computer program is stored. When the computer program is executed by a computer, the computer executes the method described in the present invention.
[0124] The computer-readable storage medium may include a read-only memory ROM, a random access memory RAM, an EEPROM, a CD ROM or other optical disk storage device, a disk storage device or other magnetic storage device, a flash memory, a USB flash drive, a mobile hard disk, or any other medium that can be used to store a desired program code in the form of an instruction or data structure and can be accessed by a computer. In addition, any connection can be appropriately referred to as a computer-readable medium. For example, if the instruction is sent from a website, a server or other remote source using a coaxial cable, an optical fiber cable, a twisted pair, a digital subscriber line (DSL), or wireless technologies such as infrared, radio, and microwaves, the coaxial cable, optical fiber cable, twisted pair, DSL, or wireless technologies such as infrared, radio, and microwaves are included in the definition of the medium. However, it should be understood that computer-readable and writable storage media and data storage media do not include connections, carriers, signals, or other temporary media, but are intended to be non-temporary, tangible storage media. Illustratively, disks and discs include compact disc (CD), laser disc, optical disc, digital versatile disc (DVD), floppy disk and Blu-ray disc where disks usually reproduce data magnetically, while discs reproduce data optically with lasers.
[0125] The present invention further provides an electronic device, comprising a memory, a processor, and a computer program stored in the memory and executable on the processor, wherein the processor implements the method described in the present invention when executing the computer program, wherein the number of the processors may be one or more.
[0126] The processor can be a general-purpose processor, including a central processing unit (CPU), a network processor (NP), etc.; it can also be a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field programmable gate array (FPGA) or other programmable logic devices, discrete gate or transistor logic devices, discrete hardware components.
[0127] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit them; although the present invention has been described in detail with reference to the above embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the above embodiments, or replace some of the technical features therein by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A method for analyzing whether mutations are located in the same gene haplotype, characterized in that: The following steps are involved: (1) performing multi-allelic site splitting using data including a mutation result file, a sample comparison result file, a gene transcript file, and information on the mutation site to be analyzed as input parameters to obtain a split mutation result file; (2) performing HGVS correction on the split mutation result file to obtain corrected data; (3) performing site-automatic review on the corrected data to obtain a set of supporting reads for each mutation site to be analyzed; (4) Determine the difference and intersection of the sets. If the number of supporting reads in the intersection is greater than or equal to 3 and greater than or equal to the minimum number of supporting reads in all differences, then the mutations to be analyzed are determined to be located in the same gene haplotype; otherwise, the mutations to be analyzed are determined not to be located in the same gene haplotype.
2. The method for analyzing whether mutations are located in the same gene haplotype according to claim 1, characterized in that: The mutation includes mutations at at least two sites, and the distance between the sites is less than the sequencing read length.
3. The method for analyzing whether mutations are located in the same gene haplotype according to claim 1, characterized in that: The sample includes a tumor tissue sample or a fluid sample.
4. The method for analyzing whether mutations are located in the same gene haplotype according to claim 1, characterized in that: The multi-allelic site splitting includes the step of splitting the alleles of the test sample genome sequence separated by a separator in the mutation result file into multiple lines, wherein the bases of the test sample genome sequence are corrected according to the difference between the bases of the split test sample genome sequence and the reference bases to obtain the corrected base information, and the physical position of the mutation site is corrected according to the base information of the corrected test sample genome sequence and the reference base information; Preferably, the multi-allelic site splitting further includes annotation information of the split mutations; Preferably, the annotation information includes allelic balance, allelic balance probability, the total number of all mutant alleles, allele frequency, number of reads supporting a specific mutant allele, CIGAR value of a specific mutant allele, depth ratio of a specific mutant allele, probability of end positioning, length of a specific mutant allele, number of reads supporting the reverse chain of the mutant allele, number of reads supporting the forward chain of the mutant allele, and mutation type.
5. The method for analyzing whether mutations are located in the same gene haplotype according to claim 1, characterized in that: The HGVS correction includes: (a) Input mutation detection results: the mutation detection results include the type, position and reference sequence of the mutation; (b) mutation classification: classifying the mutation detection results to obtain c-point mutations and p-point mutations; (c) performing c point mutation correction and p point mutation correction respectively; (d) Mutation annotation.
6. The method for analyzing whether mutations are located in the same gene haplotype according to claim 4, characterized in that: The c point mutation correction comprises: Identify cDNA sequences: Determine cDNA sequences based on reference genome and transcript information; Mutation mapping: Mapping sequencing reads onto cDNA sequences to determine the exact location of the mutation; Splice site analysis: Check whether the mutation is located at or near the splice site; Coding region analysis: determine whether the mutation is located in the coding region and analyze its effect on the coding sequence; Preferably, the p-point mutation correction comprises: Protein sequence determination: translating the cDNA sequence into a protein sequence; Prediction of mutation effects: Analyze the impact of mutations on protein sequences; Functional domain analysis: determine whether the mutation occurs in the functional domain or structural domain of the protein; Genetic codon table correction: Correction of mutation annotation errors.
7. The method for analyzing whether mutations are located in the same gene haplotype according to claim 1, characterized in that: The automated audit includes: (1') Determine that the read alignment quality of the supporting site is higher than 30; (2') confirm that the quality of the mutated base is higher than 20; (3′) confirm that the mutation position is not located at the end of the read segment; (4′) determining that the edit distance tag of the read segment is less than 4; (5') Confirm that there is no plus-minus strand preference and that the mutation site is not located in a genomic repetitive region.
8. A device for analyzing whether mutations are located in the same gene haplotype, characterized in that: include: A data acquisition unit, which is used to acquire sample sequencing reads from a sequencing device, and perform data analysis based on the sequencing reads to obtain data to be split including a mutation result file, a sample comparison result file, a gene transcript file, and information on mutation sites to be analyzed; A data splitting unit, which is used to split the data to be split into multiple alleles to obtain a mutation result file after the splitting; An HGVS correction unit, which is used to perform HGVS correction on the split mutation result file to obtain corrected data; A site automated review unit, which is used to perform site automated review on the corrected data to obtain a set of supporting read segments for each mutation site to be analyzed; A result determination unit is used to determine the difference and intersection of the sets, determine whether the mutations are located in the same gene haplotype, and if the number of supporting reads in the intersection is greater than or equal to 3 and greater than or equal to the minimum number of supporting reads in all differences, then the mutations to be analyzed are determined to be located in the same gene haplotype; otherwise, it is determined that the mutations to be analyzed are not located in the same gene haplotype.
9. A computer-readable storage medium, characterized in that The computer-readable storage medium stores a computer program, and when the computer program is executed by a processor, the steps of the method according to any one of claims 1 to 7 are implemented.
10. An electronic device, characterized in that The method comprises a memory, a processor, and a computer program stored in the memory and executable on the processor, wherein the processor implements the steps of the method according to any one of claims 1 to 7 when executing the computer program.
Citation Information
Patent Citations
Method for simultaneously detecting T790M and C797S cis-trans mutation of EGFR (Epidermal Growth Factor Receptor) gene
CN115798584A
